GLA
CORT icon

Great Lakes Advisors’s Corcept Therapeutics CORT Stock Holding History

Great Lakes Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-335,895
Closed -$10.9M – 816
2023
Q4 		$10.9M Sell
335,895
-5,583
-2% -$153K 0.1% 188
2023
Q3 		$9.3M Sell
341,478
-4,993
-1% -$145K 0.08% 205
2023
Q2 		$7.71M Sell
346,471
-2,339
-0.7% -$53.8K 0.08% 241
2023
Q1 		$7.56M Sell
348,810
-19,057
-5% -$418K 0.07% 270
2022
Q4 		$7.47M Sell
367,867
-8,988
-2% -$225K 0.43% 61
2022
Q3 		$9.66M Sell
376,855
-7,376
-2% -$197K 0.21% 127
2022
Q2 		$9.14M Sell
384,231
-5,768
-1% -$126K 0.18% 145
2022
Q1 		$8.78M Buy
+389,999
New +$8.3M 0.14% 176

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Great Lakes Advisors's CORT Position: Q1 2024 in Review

Great Lakes Advisors sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 335,895 shares — an estimated $10.9M sold.

Great Lakes Advisors first reported a position in CORT in Q1 2022 and held it in 8 quarters. The position peaked at $10.9M in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Great Lakes Advisors reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Great Lakes Advisors sold 335,895 Corcept Therapeutics shares in Q1 2024, an estimated $10.9M.
  • Great Lakes Advisors first reported a position in Corcept Therapeutics in Q1 2022 and held it in 8 quarters.
  • Great Lakes Advisors's Corcept Therapeutics position peaked at $10.9M in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Great Lakes Advisors's 13F filing for Q1 2024, filed 8 May 2024.